Cerevel Therapeutics Holdings Stock Analysis

Cerevel Stock Analysis Notes

About 15.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.67. Cerevel Therapeutics had not issued any dividends in recent years. The entity had 1:1 split on the 28th of October 2020. Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts. Cerevel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 258 people. For more info on Cerevel Therapeutics Holdings please contact Richard Hamilton at 844 304 2048 or go to https://www.cerevel.com.

Cerevel Therapeutics Investment Alerts

Cerevel Therapeutics Upcoming and Recent Events

Cerevel Largest EPS Surprises

View All Earnings Estimates

Cerevel Stock Institutional Investors

Note, although Cerevel Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cerevel Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.64 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cerevel Therapeutics's market, we take the total number of its shares issued and multiply it by Cerevel Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Cerevel Profitablity

Management Efficiency

Cerevel Therapeutics has return on total asset (ROA) of (0.2473) % which means that it has lost $0.2473 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7244) %, meaning that it created substantial loss on money invested by shareholders. Cerevel Therapeutics' management efficiency ratios could be used to measure how well Cerevel Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of April 26, 2024, Return On Tangible Assets is expected to decline to -0.37. In addition to that, Return On Capital Employed is expected to decline to -0.41. At present, Cerevel Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 3.6 M, whereas Return On Tangible Assets are forecasted to decline to (0.37).

Technical Drivers

As of the 26th of April, Cerevel Therapeutics shows the Mean Deviation of 0.4153, standard deviation of 0.6774, and Risk Adjusted Performance of 2.0E-4. Cerevel Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for thirteen technical drivers for Cerevel Therapeutics Holdings, which can be compared to its peers. Please confirm Cerevel Therapeutics information ratio and potential upside to decide if Cerevel Therapeutics is priced correctly, providing market reflects its regular price of 42.07 per share. Given that Cerevel Therapeutics has information ratio of (0.12), we suggest you to validate Cerevel Therapeutics Holdings's prevailing market performance to make sure the company can sustain itself at a future point.

Cerevel Therapeutics Price Movement Analysis

Cerevel Therapeutics Insider Trading Activities

Cerevel Therapeutics Predictive Daily Indicators

Cerevel Therapeutics Corporate Filings

Cerevel Therapeutics Forecast Models

Cerevel Therapeutics' time-series forecasting models are one of many Cerevel Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cerevel Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cerevel Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cerevel shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cerevel Therapeutics. By using and applying Cerevel Stock analysis, traders can create a robust methodology for identifying Cerevel entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cerevel analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cerevel analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Cerevel Therapeutics Holdings stock analysis indicators help investors evaluate how Cerevel Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cerevel Therapeutics shares will generate the highest return on investment. By understating and applying Cerevel Therapeutics stock analysis, traders can identify Cerevel Therapeutics position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cerevel Therapeutics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

When running Cerevel Therapeutics' price analysis, check to measure Cerevel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cerevel Therapeutics is operating at the current time. Most of Cerevel Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cerevel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cerevel Therapeutics' price. Additionally, you may evaluate how the addition of Cerevel Therapeutics to your portfolios can decrease your overall portfolio volatility.

Is Cerevel Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cerevel Therapeutics. If investors know Cerevel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cerevel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Cerevel Therapeutics is measured differently than its book value, which is the value of Cerevel that is recorded on the company's balance sheet. Investors also form their own opinion of Cerevel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cerevel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cerevel Therapeutics' market value can be influenced by many factors that don't directly affect Cerevel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cerevel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cerevel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cerevel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.